Repel and kill film formulation shows approximately 99.8% reduction in adhesion of bacteria to the surface and at least 99.6% killing of residual bacteria on the surface

Oakville, Ontario--(Newsfile Corp. - November 29, 2023) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection coatings, is pleased to announce the publication of results from research conducted at McMaster University ("McMaster") demonstrating that a film formulation combining photoactive nanoparticles and fluorosilane not only repels bacteria but also exhibits killing properties after exposure to light for one hour. This data was published on November 17, 2023 in "ACS Applied Materials and Interfaces."

Dr. Carolyn Myers, President and CEO of FendX, stated, "As we continue our research and development efforts with McMaster to further our pipeline of potential products and to advance our nanotechnology, we are pleased with the results of this bifunctional formulation which significantly reduces bacterial contamination." Dr. Myers continues, "We believe this is the first surface protective coating that has both repelling and killing properties, which may provide even further reduction in pathogen adhesion and transmission compared to products that either only repel or kill pathogens."

The bifunctional nano-coated film formulation combines photoactive TiO₂ nanoparticles with fluorosilane followed by thermal shrinking to create a surface that both repels and kills bacteria. A touch-based assay was used to simulate the transfer of different pathogens (Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa and MRSA) from hands to the film surface and demonstrated repelling properties of at least 99.8%. The antimicrobial activity of the TiO₂ nanoparticles killed bacteria transferred to the surface by 99.6% after one hour of light exposure. (See the publication in this link). The Company's focus will be to continue to develop its most advanced film project, REPELWRAP film, which is under intermediate scale-up development with Dunmore International Corp.

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

Contacts:

Dr. Carolyn Myers, CEO and Director
1-800-344-9868

Alyssa Barry, Investor Relations
1-833-947-5227
investor@fendxtech.com

For more information, please visit and the Company's profile on SEDAR+ at .

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the Company's advancement of its nanotechnology including intermediate scale-up efforts on REPELWRAP film repel formulation; statements regarding the Company's belief that this is the first surface protective coating that has both repelling and killing properties, which may provide even further reduction in pathogen adhesion and transmission compared to products that either only repel or kill pathogens; and products under development and any pathogen reduction or killing benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate, and that actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company's public filings which are available on SEDAR+ at . Accordingly, the reader is urged to refer to the Company's such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors should change.

To view the source version of this press release, please visit